Moreno Evelyn V Cuts Holdings in Johnson & Johnson (JNJ)
Moreno Evelyn V lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,553 shares of the company’s stock after selling 1,515 shares during the quarter. Johnson & Johnson comprises approximately 2.3% of Moreno Evelyn V’s portfolio, making the stock its 13th biggest holding. Moreno Evelyn V’s holdings in Johnson & Johnson were worth $7,613,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of JNJ. State Street Corp boosted its position in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. Korea Investment CORP boosted its position in Johnson & Johnson by 38.9% during the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock worth $265,296,000 after purchasing an additional 596,134 shares during the period. Bank of Nova Scotia boosted its position in Johnson & Johnson by 94.5% during the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after purchasing an additional 569,313 shares during the period. Oppenheimer Asset Management Inc. bought a new position in Johnson & Johnson during the first quarter worth about $65,598,000. Finally, CIBC World Markets Inc. boosted its position in Johnson & Johnson by 111.8% during the first quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock worth $118,155,000 after purchasing an additional 500,662 shares during the period. Hedge funds and other institutional investors own 65.90% of the company’s stock.
In other news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.
A number of equities analysts have recently commented on JNJ shares. J P Morgan Chase & Co raised their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Tuesday, August 15th. Wells Fargo & Company restated a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. BidaskClub lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Cowen and Company set a $147.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, August 24th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $135.29.
Johnson & Johnson (JNJ) traded down 0.27% on Friday, hitting $131.39. 4,334,862 shares of the company’s stock traded hands. The stock has a market cap of $352.65 billion, a P/E ratio of 22.23 and a beta of 0.79. The stock has a 50 day moving average price of $132.79 and a 200-day moving average price of $129.43. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.74 EPS. Equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.